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ABSTRACT 
 
 Campylobacter are a leading cause of bacterial derived foodborne illness. 
Thymol is a natural product that reduces survivability of Campylobacter in vitro. Results 
from animal studies, however, indicate that absorption or degradation within the stomach 
and small intestine may preclude delivery of thymol to the cecum and large intestine, the 
main sites of Campylobacter colonization. Presently, we compared the anti-
Campylobacter activity of thymol against that of thymol-β-D-glucopyranoside (β-D-
thymol), the latter suspected to be resistant to degradation and absorption in the proximal 
alimentary tract lacking β-glycosidase activity. When treated with 1 mM thymol, the 
survivability of Campylobacter coli and jejuni in vitro was reduced by 3.41 to 6.87 log10 
CFU mL-1 after 48-h pure culture and after co-culture, respectively. In the presence of  a 
β-glycosidase-expressing Parabacteroides distasonis. Conversely, the survivability of C. 
coli and C. jejuni was reduced by 3.72 and 4.30 log10 CFU mL-1, respectively, in co-
cultures treated with β-D-thymol, but not in pure cultures similarly treated. When tested 
in mixed cultures of porcine or bovine fecal microbes possessing endogenous β-
glycosidase, C. coli and C. jejuni survivability was reduced by 3.26 and 2.50 log10 CFU 
mL-1, respectively, whether treated with thymol or β-D-thymol. In mixed populations of 
avian crop and cecal microbes, C. jejuni survivability was reduced 1.41 to 2.32 log10 
CFU mL-1 whether treated with thymol or β-D-thymol. Thymol and β-D-thymol 
inhibited ammonia accumulation in mixed populations of porcine and mixed bovine 
fecal microbes which is consistent with free thymol’s purported role as a deaminase 
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inhibitor. Conversely, thymol and β-D-thymol did not affect ammonia accumulation in 
mixed populations of avian gut microbes implicating population specific effects of these 
compounds. β-D-thymol, but not thymol, reduced accumulation of fermentation acids 
indicating the conjugate inhibited fermentation which may limit its application to the last 
meal or last few meals before harvest.  Oral administration of 150 µmol β-D-thymol 
reduced C. jejuni in avian crop, but not in cecal contents; treatment with thymol was 
ineffective. These results indicate that β-D-thymol, or similar β-glycosides, may be a 
suitable candidate to escape absorption and degradation within the proximal alimentary 
and retain its anti-Campylobacter properties. Further research is needed to reduce such 
technology to practice.   
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NOMENCLATURE 
 
ATP Adenosine Triphosphate 
β–D-Thymol Thymol-β-D-Glucopyranoside 
CFU                             Colony Forming Units 
GBS Guillian Barre Syndrome 
MFS Miller Fischer Syndrome 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Introduction 
Campylobacter spp. are a leading cause of bacterial associated human foodborne 
illness in the United States. Campylobacteriosis is estimated to affect over 1 million 
people every year and to cause 100 deaths. The cost of human illness is $1.3 to $6.2 
billion annually (1, 2). Campylobacter can also cause post-infection complications 
associated with acquired immune-mediated neuropathies such as Guillian Barre 
Syndrome or Miller Fischer Syndrome (3, 4). Most human Campylobacter infections are 
caused by Campylobacter jejuni; however 4% of clinically confirmed cases in one study 
were attributed to Campylobacter coli (5). Usually cattle and poultry are colonized with 
Campylobacter jejuni and pigs are colonized with Campylobacter coli. However, 
considerable numbers of pigs can be colonized with Campylobacter jejuni (6, 7). 
Campylobacter are also recognized as reservoirs for antimicrobial resistance genes that 
potentially can be exchanged between other pathogenic and commensal bacteria (8-11). 
Poultry, swine and cattle can harbor these pathogens within their digestive tracts and risk 
contaminating the carcass when it is presented for processing.  
Unlike many other gut bacteria, Campylobacter are limited in their ability to 
conserve energy for growth and maintenance via fermentation of carbohydrates. These 
bacteria lack 6-phophofructokinase, which is a key enzyme in energy metabolism (12). 
Campylobacter can conserve energy via respiration, oxidizing hydrogen and formate for 
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the reduction of electron acceptors such as fumarate, nitrate, sulfites and if at low 
concentrations, oxygen, to generate proton motive force transport phosphorylization (13-
17). It is unclear how much growth can be supported by this process, since 
concentrations of these electron acceptors are typically low within the gut environments.  
Campylobacter have the capability to catabolize amino acids such as aspartate, 
alanine, glutamate, glutamine, methionine and serine at a substrate-level to store energy 
(18-20). Intermediate and end products of amino acid catabolism by Campylobacter 
include acetate, formate, fumarate, lactate, pyruvate and succinate, thus indicating that 
the involvement of mixed acid fermentation and reductive metabolism of the 
tricarboxcylic acid pathway (21, 22).  
The purported deaminase inhibitor thymol, an extract of thyme, is a natural 
product that markedly reduces survivability of Campylobacter in vitro. Thymol 
disintegrates the outer membrane of Gram-negative bacteria releasing 
lipopolysaccharides and increasing the permeability of the cytoplasmic membrane to 
ATP. ATPases are located in the cytoplasmic membrane and are bordered by lipid 
molecules. There are two suggested mechanisms where cyclic hydrocarbons act: 1) 
hydrocarbon molecules accumulate in the lipid bilayer and distort the lipid-protein 
interaction; 2) direct interaction exists between the lipophilic compounds the 
hydrophobic parts of the protein (23-25). Although there is still some debate about the 
mechanism of action of thymol, previous studies have shown thymol to be effective in 
reducing microbial growth (24, 26, 27). However, results from in vivo studies revealed 
that thymol is absorbed in the stomach and small intestine, thereby preventing delivery 
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of efficacious amounts of thymol to the cecum and large intestine where Campylobacter 
reside (28). 
 This study proposes that attaching thymol to glucose to form a thymol-β-D-
glucopyranoside that will make it a suitable product capable of bypassing the stomach 
and small intestine. The enzyme β-D-glucosidase, which is present in bacteria, molds, 
and yeast, retains catalytic activity over the pH range 2.0-9.5. This enzyme exhibits D-
galactosidase activity that should act as a hydrolysis mechanism that can release thymol 
from the β-D-glucopyranoside once delivered to the cecum and large intestine.  
Reduction of food borne pathogens prior to slaughter could reduce human 
exposure to pathogens and thus reduce the numbers of human food borne illnesses. The 
use of natural essential oils, such as thymol and thymol derivatives, in place of 
traditional antibiotics can lead to viable treatments that will lessen dependence on 
antibiotics and reduce the occurrence of food borne illness in humans. The overall 
project goal is to develop and produce a practical, cost effective, and easy way to 
implement pre-harvest strategy to reduce the incidence and concentration of 
Campylobacter in the gut of food-producing animals immediately prior to processing. 
 
Literature Review 
Campylobacter species 
Campylobacter spp. are Gram-negative spiral non-spore forming rods that form 
spherical or coccoid bodies in older cultures. They are between 0.2 to 0.9 microns wide 
and 0.5 to 5 microns long, are motile and usually move with a polar unsheathed 
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flagellum at one or both ends, and are microaerobic with a respiratory-type metabolism, 
although there are some that grow aerobically or anaerobically (29). 
 The Campylobacter jejuni genome is a relatively small genome; 1.6-1.7 Mbp of 
adenine and thymine-rich DNA content and the guanine and cytosine content ranges 
from 29 to 47% (30-32). Campylobacter spp. is one of the leading causes of bacterial- 
associated human foodborne illness in the United States. The rate of Campylobacter 
infections is increasing worldwide, exceeding shigellosis and sometimes exceeding 
salmonellosis (33, 34).  
The infectious diseases caused by members of the bacterial genus Campylobacter 
are called campylobacteriosis (34). Currently Campylobacter jejuni (C. jejuni) and 
Campylobacter coli (C. coli) are considered to be the most important enteropathogens 
among Campylobacter spp. (35). 
 Campylobacter history 
 From a historical standpoint, the first report of Campylobacter species is 
believed to have been made in 1886 by Theodore Escherich, who observed and 
described a non-culturable spiral shaped bacteria, which he found in the colon of 
children with an enteric disease called, “cholera infantum” (30, 36-38). Campylobacter 
was identified in 1913 by two British veterinarians, J. McFadyean, and S. Stockman. 
McFadyean and Stockman reported the presence of “large numbers of a peculiar 
organisms” in the uterine mucus of a pregnant sheep (36, 39-41). In 1927 a group of 
vibrio-like bacteria was found in the feces of cattle with diarrhea. They were described 
by Theobold Smith and Marion Orcutt (35, 42, 43). In 1931, S.F. Jones and coworkers 
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showed a relationship between the microaerophillic vibrios and bovine dysentery, and 
the organism was eventually called Vibrio jejuni. The first well documented incident of 
Campylobacter infection took place in Illinois in 1938. The case involved a milk-borne 
outbreak of diarrhea that affected 355 inmates in two adjacent state institutions (41, 44). 
In 1944, Michael P. Doyle isolated another vibrio from the feces of pigs with diarrhea 
and classified it as Vibrio coli (35, 45). Because of their low DNA base (Low Guanine 
and Cytosine) composition, non-fermentative metabolism and their microaerophillic 
growth requirements the genus Campylobacter was proposed by Seabald and Vernon in 
1963, distinguishing them from the Vibrio spp. (36, 46). There are two subspecies 
recognized within C. jejuni, C. jejuni subspecies jejuni and C. jejuni subspecies doylei. 
Strains of doylei differ from jejuni biochemically. Campylobacter coli and C. jejuni 
differ biochemically in their ability to hydrolyze hippurate. Campylobacter coli cannot 
hydrolyze hippurate and there are some C. jejuni subspecies that are hippurate negative 
(35). 
 Campylobacter metabolism  
Campylobacter genus members are limited in their ability to conserve energy for 
growth via fermentation of carbohydrates due to the absence of two key components of 
the Embden-Meyerhof-Parnas pathway: The first component is the phosphoenolpyruvate 
dependent phosphotransferase system, which transports and phosphorylates sugars 
simultaneously, and the second component is phosphofructokinase, which catalyzes the 
conversion of fructose-6-phosphate to fructose 1,6-biphosphate (12, 35). Campylobacter 
can conserve energy via respiration, oxidizing hydrogen and formate for the reduction of 
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the electron acceptors (fumarate, nitrate, sulfites) and, if at low concentrations, oxygen, 
to generate proton motive force for electron transport phosphorylation (12-16). 
Campylobacter jejuni relies on the use of the amino acids and the citric acid cycle 
intermediates as carbon sources (47). There are some C. jejuni subspecies doylei which 
contain some enzymes from the Enter-Deudoroff pathway which convert glucose-6-
phosphate to glyceraldehyde-3-phosphate utilizing gluconate-6-phosphate instead of a 
fructose-6-phosphate intermediate. This pathway eliminates the need for 
phosphofructokinase (35). It has generally been assumed that C. jejuni were found to 
contain genomic islands (cj0480c-cj0490) that are up regulated in the presence of L-
fucose and mucin obtained from the host during colonization in the intestine (48). The 
current knowledge of C. jejuni in vivo metabolism is based on amino acid utilization to 
support the growth and establishment of colonization in the host intestines. 
Campylobacter jejuni metabolic diversity is evidenced by its differential carbon 
utilization (49-51).  
Campylobacter antimicrobial resistance  
 Antibiotic resistance is primarily due to genetic mutations in bacteria causing 
resistance to the drug and allowing for survival of the pathogen. Many of these resistant 
genes are located on plasmids, allowing for easy transfer. A 2011 review published in 
Frontiers in Microbiology hypothesizes that the unregulated use of antimicrobial agents 
in food animal production has led to the emergence and spread of antibiotic resistance 
among Campylobacter spp. The evidence of this is strongly supported (36). Antibiotics 
have been used for decades in food production animals to control, prevent, and treat 
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infections and to enhance growth (36, 52-54). This usage has caused an increased 
resistance to multiple antibiotics by members of Campylobacter spp. in food production 
animals and environments (36, 55). Food production animals are considered to be  the 
primary source of Campylobacter infections in humans, thus the development of 
antimicrobial resistance in Campylobacter spp. is a serious threat to human health (36).  
Worldwide, there has been a rapid increase in the proportion of Campylobacter 
strains resistant to antimicrobial agents (56-59). Campylobacter jejuni and C. coli are 
almost universally resistant to penicillians, cephalosporins (with exception of a few 3rd 
generation cephalosporins), trimethoprem, sulfamethoxazole, rifampicin and 
vancomycin (35). Campylobacter jejuni and C. coli cause a broad range of illnesses in 
humans. Fevers, abdominal cramping, and diarrhea, with or without blood in stools, are 
distinct features of an uncomplicated illness that could last from a few days up to a week 
(35, 60). The prognosis is that most patients infected with Campylobacter spp. will 
recover without specific treatments other than replacement of fluid and electrolytes, 
despite the fact that in more severe cases generally antibiotics such as macrolides, 
tetracycline,  and fluroquinolones are administered (61). It is believed that increasing 
resistance to fluroquinolones, tetracycline, and erythromycin by C. jejuni and C. coli 
might compromise the effectiveness of these treatments (8, 36, 62-64).  
Human estimates 
 In 2005, the Centers for Disease Control and Prevention (CDC) estimated that 
the number of campylobacteriosis cases in the United States was about 1 million per 
year. In 2005, Campylobacter was the second leading cause of laboratory confirmed 
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cases of foodborne illness in the United States, with an estimated 12.72 cases per 
100,000 people, for a total of 5,655 cases (65). In 2009, the Foodborne Disease Active 
Surveillance Network (FoodNet)  of the CDC estimated that the number of infections by 
Campylobacter was a total of 6,033, or 13.02 per 100,000 people (36). In the last five 
years the European Food Safety Authority (EFSA) and the European Centre for Disease 
Prevention and Control (ECDC) reported that campylobacteriosis has become the most 
often reported zoonosis in the European union followed by salmonellosis and yersinosis 
(36, 66, 67). More than 200,000 confirmed cases of campylobacteriosis were reported in 
24 of the member states of the European Union at a rate of 45.2 cases per 100,000 
people. In 2010 New Zealand  reported the highest national campylobacteriosis rate, 
which peaked in May 2006 at 400 per 100,000 population (36).  
In general, developing countries do not have national surveillance programs for 
campylobacteriosis; thus, there are no case incidence values in terms of population 
density (33). Most of the estimates of incidence are done by laboratories where the 
surveillance is based on pathogens responsible for diarrhea.     
Campylobacter isolation rates range from 5 to 20% in developing countries (33, 
68). Most of the data are collected by the World Health Organization (WHO).The WHO  
and the Canadian Public Health Service have provided financial support to developing 
countries for epidemiologic studies (33, 69). There is a large disparity in the incidence of 
campylobacteriosis in developing countries versus that of developed countries. High 
numbers of children in developing countries are affected by Campylobacter. Community 
based studies in developing countries have estimated that 60,000 per 100,000 children < 
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5 years of age (33, 68, 70) are infected; whereas, in developed countries 300 per 100,000 
are affected (33, 71). Estimates for the general population in developing and developed 
countries are relatively similar at approximately 90 per 100,000 affected by 
campylobacteriosis (33, 69, 71). This result suggests that campylobacteriosis is a 
pediatric disease in developing countries. In developed countries, more than 90% of 
human campylobacteriosis cases occur during the summer because of undercooked 
meats from outdoor cooking facilities. People of all ages are affected, but particularly 
children less than 4 years of age and young adults 15-44 years of age (2, 41). 
 The infectious dose of Campylobacter jejuni for humans is estimated to be low; 
between 500-800 organisms. The dosage was estimated in 1981 as a result of a human 
experiment in which a British medical doctor, D.A. Robinson, swallowed 500 organisms 
of known serotype in 180 ml of pasteurized milk. The findings from this self-inflicted 
experiment, which reportedly satisfied the criteria of Koch’s Postulates and the findings 
of additional human experiments, verified a dosage and a mechanism of C. jejuni human 
infection (35, 72). In industrialized countries, clinical signs of campylobacteriosis are 
characterized by acute self-limited gastrointestinal illness with abdominal cramps, 
diarrhea and fever. The incubation period is from 2 to 7 days (41). In severe cases of C. 
jejuni infection, individuals may exhibit fever, abdominal cramps and diarrhea that 
contain blood and leukocytes, or they may develop post infection complications 
associated with Guillian-Barre Syndrome (GBS) or Miller Fischer Syndrome (MFS). 
MFS is a subform of GBS characterized by areflexia, ataxia and opthalmoplegia (35, 
73).  
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Campylobacter pathogenesis and disease 
 The exact sequential steps of C. jejuni infection to C. jejuni mediated enteritis 
are unknown. What is known are the requirements for C. jejuni virulence: 1) motility, 2) 
drug resistance, 3) host cell adherence, 4) host cell invasion, 5) alteration of the host cell 
signaling pathways, 6) induction of host cell death, 7) evasion of the host 8) immune 
system defenses, and 9) acquisition of iron which serves as a micronutrient for growth 
and works as a catalyst for hydroxyl radical formation (74, 75). It is also known that C. 
jejuni secretes proteins that contribute to the ability of the bacterium to invade the host 
epithelial cells. A suggested model for C. jejuni pathogenesis shows the first step as the 
consumption of C. jejuni contaminated food or food products. Survival in the host 
environment depends on several adaptive responses including adherence, protein 
secretion, invasion and replication.  
The biochemical effects on cellular events are as follows: 1) cytoskeletal 
rearrangement, 2) host cell death, 3) tight junction disruption and cytokine induction that 
leads to loss of epithelial cell function, 4) a compromised barrier and absorptive 
functions, and 5) tissue destruction and disease manifestation. Adherence can also lead 
to an early inflammatory response that causes stimulation of innate immune functions in 
the following sequence; 1) an influx of fluid, 2) complement cell activation, 3) 
recruitment of phagocytes that can lead to C. jejuni lysis or death, 4) clearing of the 
infection or the presentation of antigens, 5) a humoral response and, 6) a clearing of the 
infection. In the other direction, instead of C. jejuni lysis or death, the inflammatory 
response could lead to tissue destruction  and disease manifestation (74). 
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 There is evidence that C. jejuni infections commonly precede GBS conditions 
that trigger antibodies which cross react with gangliosides and damage peripheral nerve 
tissue. In patients who exhibit a C. jejuni infection preceding GBS, GBS is considered to 
be a disease mediated case of molecular mimicry (35). GBS is a rare autoimmune 
disease characterized by the demyelination of motor and sensory nerves or deterioration 
of axonal nerves of the peripheral nervous system. This nerve damage can lead to muscle 
weakness, paralysis, and death. It is reported that GBS “has become the most frequent 
cause of acute flaccid paralysis since the near elimination of poliomyelitis in the world” 
(4, 76-78).   
Studies have established GBS as a mechanism of molecular mimicry based on 
Koch’s and Witebsky’s postulates. They are as follows: 1) the establishment of an 
epidemiological association between the infectious agent and the autoimmune disease, 2) 
the identification of T cells or antibodies directed against the patient’s target antigens, 3) 
the identification of microbial mimics of the target antigen, and 4) reproduction of the 
disease in an animal model. Autoantibodies are the pathogenic component that triggers 
GBS (77). 
There are two major sub-forms of GBS that affect the peripheral nervous system. 
The major sub-forms of GBS are: 1) acute inflammatory demyelinating polyneuropathy 
(AIDP) characterized by the demyelination of peripheral nerves, 2) acute motor axonal 
neuropathy (AMAN) characterized by degeneration of axonal components of peripheral 
nerves, and 3) Miller Fischer syndrome (MFS) characterized by areflexia, ataxia, and 
ophthalmoplegia. Studies have indicated that C. jejuni infection precedes GBS in 20 to 
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50% of cases in Europe, North and South America, Japan, and Austraila. The percentage 
is suspected to be higher in developing countries. Since Campylobacter infections occur 
far more frequently than GBS, neither the characteristics of the host nor the strain of 
Campylobacter species are known determinants of which persons with Campylobacter 
infection contract GBS. Guillian Barre Syndrome usually develops 1 to 3 weeks after a 
C. jejuni infection. Studies in Japan have indicated that the risk of developing GBS may 
be higher after infection with C. jejuni type O:19 (4, 35, 76).  
Pathogenic reservoirs and vehicles 
 Reservoirs are any living or nonliving thing (person, animal, plant, soil, or 
substance) in which an infectious agent multiplies and develops. Infectious agent 
reservoirs typically harbor the infectious agent without injury and serve as vehicles that 
can transmit the infection. The infectious agent depends on the reservoir for its survival. 
The infectious substance is transmitted from the reservoir to a human or another 
susceptible host (79). Reservoirs for C. jejuni and C. coli are as follows: 1) cattle, 2) 
poultry, 3) pigs, 4) sheep, 5) dogs, 6) birds, 7) apes, 8) rodents, 9) insects, 10) humans, 
11) water, and 12) food items (raw milk, pork, beef, lamb, and seafood) (80). 
Campylobacter jejuni and C. coli occur mostly as commensal organisms. 
 Vehicles are modes of horizontal and vertical transmission of infection.  
Horizontal transmission is defined as transmission of an infectious agent from an 
infected source to a susceptible contemporary, and vertical transmission is defined as 
transmission from one generation to the next. Examples of vehicles are: 1) contact with 
undercooked/raw poultry or meat, 2) contaminated shellfish, 3) unpasteurized raw milk 
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or dairy products, 4) contaminated and inadequately treated drinking water, and (5) 
contact with animals, especially young animals (puppies) with diarrhea 
(58).Transmission routes are: fecal-oral, person-to-person, sexual contact, and direct 
person-to-person contact which is a rare. There is also speculation that Campylobacter, 
when stressed, enter a viable but non-culturable state characterized by an uptake of 
amino acids and maintenance of an intact outer membrane (spore like state). In this state 
organisms can be transmitted to animals. Vehicles and reservoirs are mostly 
synonymous modes of C. jejuni and C. coli infection transmission. Even though all 
reservoirs can act as vehicles, not all vehicles can act as reservoirs. The distinction being 
that reservoirs allow for the growth and multiplication of enteropathogens through a 
commensal relationship, whereas, vehicles only allow for transmission of the pathogen. 
Incidence of Campylobacter infection 
 From animal farm production to the commercial production of food commodities 
there are numerous possibilities for transmission of Campylobacter infection through 
cross-contamination. Campylobacter infection from consumption of poultry, beef, and 
pork products is the leading cause of human foodborne illness. Poultry is estimated to 
account for 50-70% of human Campylobacter infection. Live poultry includes broilers, 
laying hens, turkeys, ducks, and ostriches (35). Studies have indicated that the 
prevalence of Campylobacter colonization in cattle is 0-80% and 20% in sheep. The 
same study reported that pigs were more contaminated than cattle or sheep (81). 
 Poultry and poultry products are considered to be the largest contributor of 
human Campylobacter infection. Campylobacter jejuni mainly colonizes poultry and is 
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found predominantly in the cecum and colon, but it can also be found in the crops. 
Horrocks et al. believe that due to the higher metabolic temperatures of the poultry 
species they are possibly predisposed to become prominent reservoirs for the 
thermotolerant C. jejuni (82). 
Campylobacter transmission is prevalent during preharvest conditions. 
Colonization in broiler chicks has been demonstrated to be a risk factor in horizontal 
transmission of C. jejuni infection. Broiler chick colonization is estimated to take place 
no sooner than seven days of age (81, 83). Other studies have found that broiler chick 
colonization takes from zero to three weeks. Colonization of free-ranging chickens is 
estimated to take place from 0-8 days (82, 84-86). Although young animals are very 
susceptible to colonization by C, jejuni, older broiler chicks closer to processing age 
have a higher percentage of Campylobacter colonization. Despite horizontal 
transmission of the flock taking place rapidly, colonization of the flock can take up to 
several weeks (82). Studies have estimated that up to 98% in the United States and 60% 
to 80% in Europe of retail chicken meat is contaminated with C. jejuni. It was found that 
the skin and giblets have particularly high concentrations of Campylobacter 
contamination. 
Despite the consistent implication that Campylobacter colonization of poultry 
and poultry products is the major contributor to human foodborne illness, cattle and 
other swine frequently carry C. jejuni and C. coli.  It is probable that cattle carcasses are 
contaminated during processing either directly or indirectly. None the less, the cases of 
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human foodborne illness as a result of Campylobacter contamination in bovine products 
(unpasteurized milk and meat) is a legitimate concern (87, 88). 
Multiple studies with cattle have shown that Campylobacter preferentially 
colonize the lower gastrointestinal tract as opposed to the upper gastrointestinal tract (the 
1st stomach) where there is a lower pH environment in the rumen. The gallbladder, liver 
and bile have all been shown to harbor moderately high percentages of Campylobacter. 
In recent studies, 33% and 21.8% respectively of samples tested positively for 
Campylobacter in the gallbladder, its mucosal tissue and bile (82). Unpasteurized bovine 
milk and milk products are common vehicles for Campylobacter foodborne disease 
transmission. In a study with cattle from a dairy farm 12% of raw milk samples were 
found to be contaminated with C. jejuni possibly as a result of contact with bovine feces, 
contaminated water or direct contamination as a result of mastitis (89).   
The incidence of Campylobacter is reported to be lower for forage fed (primarily 
dairy cattle) than that of feedlot cattle. The possible contributors to the high incidence of 
Campylobacter in feedlot cattle are 1) increased stocking densities, 2) constant contact 
with feces from other animals, and 3) the high frequency of shared access to community 
feeding and water troughs (82, 90). These studies found that there was a higher 
prevalence of Campylobacter in feedlot cattle (68%) compared to that of adult cattle 
from the pasture (7.3%). These numbers remained relatively the same whether tests were 
conducted before or after transport to processing. These results suggest that confinement 
may promote increased carriage and horizontal transmission of Campylobacter. Further 
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swab tests on the hides of these cattle yielded the same results. The feedlot cattle had 
significantly more contaminated hides. 
The numbers of swine that are colonized by Campylobacter are more comparable 
to cattle than to those of poultry. Campylobacter coli, which normally inhabit pigs 
intestine, are found on pork products. Swine are predominantly colonized with C. coli 
albeit less frequently they are colonized with C. jejuni (91). Young et.al (92) 
demonstrates that despite the prevalence of C. coli in swine, a high prevalence of C. 
jejuni enteric colonization (cecal or rectal contents) has been observed in gilts, sows, and 
weaned piglets.  Studies conducted by Jensen et al. (82, 93)  investigated C. jejuni versus 
C. coli colonization of outdoor organically-reared pigs to monitor possible shifts from C. 
coli to C. jejuni intestinal colonization. There have also been research studies that 
demonstrate the possible co-existence of C. coli and C. jejuni in pigs with C. jejuni being 
present in lower numbers (93, 94).  Throughout all trials C. jejuni was never found to be 
more prevalent than C. coli. The life of swine raised for food production starts at a 
farrowing barn where they are born. After three weeks they are moved to a nursery 
where they will stay until they reach 50 lbs (6 weeks). Next they are moved to a 
finishing unit where they will stay until they reach market growth rate (220-250 lbs). In 
the finishing unit swine are held 25 per pen. Environmental conditions play an important 
role in Campylobacter transmission the same as cattle and poultry. There are increased 
possibilities for Campylobacter infection and disease transmission in finishing units and 
breeding farms (92).  There are distinct differences in the prevalence and occurrence of 
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Campylobacter colonization and infection of pigs raised in organic outdoor production 
systems than those raised in conventional farm systems (95). 
Thymol antimicrobial activity 
 Thymol (C10 H14 O), also known as 2-isopropyl-5-methylphenol, it is a natural 
product (monoterpene phenol) found in the essential oil extracted from Thymus and 
Origanum plants (Thyme and Oregano). Thymol was discovered by von Casper Neuman 
in 1719 and it was chemically synthesized and named by M. Lallemand in 1842. 
Chemically thymol is slightly soluble in water and extremely soluble in alcohols and 
other organic solvents (96). 
Historically essential oils from spices have been used as fragrances, flavoring, 
and preservatives since ancient times. Thymol and its chemical isomer carvacol were 
used by the ancient Egyptians in the preservation of mummies (24, 97). The ancient 
Greeks used thyme oil for aromatic purposes such as incense that were burned in the 
sacred temples. Thyme was also a symbol of courage to the Greeks. As early as the 16th 
century thyme oil was used for its antiseptic properties. Thymol is currently used in 
conjunction with chlorhexidine as a mouthwash (98).  
Thymol is an essential oil that belongs to a group of compounds known as 
biocides, and they are common protection mechanisms used against environmental 
stressors (herbivores, fungi, and viruses) by most plants. The low frequency of infectious 
diseases in plants suggests that  essential oils  would be  effective bactericidal agents 
(99).Thymol has bactericidal and fungicidal properties and has also demonstrated 
antimutagenic effects in combination with other essential oils. The phenolic components 
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are primarily responsible for the bactericidal properties of essential oils such as thymol 
and carvacol (24, 100).  Thymols’ active components, are generally recognized as being 
safe for human consumption in the United States, have caused researchers to examine its 
potential to improve production health in food-producing animals. Thymol has 
demonstrated bactericidal activity against Gram-negative and Gram–positive bacteria. 
Research has demonstrated that Gram-negative organisms are slightly less  susceptible to 
essential oils such as thymol than Gram-positive (24).  
Thymol’s mechanism of action is hypothesized to be disruption of the Gram-
negative bacterial cell membrane integrity, which leads to increased permeability to 
ATPases proteins (98). Cyclic hydrocarbons are lipophillic and therefore are prone to 
accumulate in lipids.  There are two suggested mechanisms where cyclic hydrocarbons 
act: (1) accumulation of lipophillic hydrocarbon molecules in the lipid bilayer and 
distortion of the lipid-protein interaction and (2) direct interaction of the lipophillic parts 
of the protein (23-25).  There is some debate about the specific mechanism of thymols’ 
action on Campylobacter. Previous in vitro studies have demonstrated that thymol 
markedly reduces the concentration of Campylobacter spp. (24, 26, 27). However in vivo 
studies have shown that thymol is absorbed in the stomach and small intestine 
preventing efficacious amounts from being delivered to the cecum and large intestine 
(28).  
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These in vivo studies indicate the need for a suitable bypass mechanism capable 
of delivery of efficacious amounts of thymol to the cecum and large intestine. Attaching 
a β-D-glucopyranoside to thymol should make it a suitable product capable of bypassing 
the stomach and small intestine. 
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CHAPTER II 
ACTIVATION OF THYMOL Β-D-GLUCOPYRANOSIDE BY BACTERIAL-
EXPRESSED Β-GLYCOSIDASE 
 
                                                         Introduction 
Campylobacter spp. are a leading cause of bacterial derived foodborne illness 
worldwide. Campylobacter can colonize the digestive tracts of food-producing animals 
at a high prevalence. Infections caused by Campylobacter originating from food-
producing animals are often resistant to a range of antibiotic agents used in food animals 
and humans. It is possible that the resistant Campylobacter and the resistant genes they 
carry can be transferred to humans by consumption of food products contaminated with 
the pathogen (99). This could lead to colonization of the human intestinal tract with the 
resistant Campylobacter genes which could change the commensal bacterial 
environment thereby risking the loss of effectiveness of antibiotics used by humans.  
Campylobacter spp. colonization of humans can also cause post infection complications 
associated with Guillian Barre Syndrome or Miller Fischer Syndrome (3, 4). Few 
strategies are available to prevent infection and carriage of contamination by carcasses at 
the processing plant and fewer yet are available to prevent infection and carriage of  
Campylobacter in animals on the farm (82). Consequently, the food animal industry is 
continually looking for new strategies capable of reducing the carriage of pathogens on 
the farm and during processing. Thymol (2-isopropyl-5-methylphenol) is a natural 
essential oil that markedly inhibits the survivability of Campylobacter in pure and mixed 
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culture in vitro (1). However, in vivo studies have demonstrated that thymol is 
extensively absorbed or degraded within the stomach and small intestine thereby 
precluding delivery of this compound to the cecum and large intestine where 
Campylobacter primarily reside (101). It is reasonable to hypothesize, however, that 
thymol conjugates bound to glucose via a β-glycosidic bond may make the bound form  
of thymol 1) more resistant to absorption and 2) more resistant to degradation within the 
proximal alimentary tract.  
Tests of the first hypothesis have demonstrated that unlike free thymol, thymol-
β-D-glucopyranoside is not appreciably absorbed or degraded in everted stomach or 
small intestinal segments (102). Regarding the second hypothesis, the β-glycoside 
should be nearly undegradable in the stomach and proximal small intestine of 
monogastrics because higher animals do not produce the β-glycosidase enzyme required 
to hydrolyze the β-glycoside. For instance, the lack of β-glycosidase enzymes in 
monogastrics is the reason why they cannot use cellulose, which is a polymer composed 
of repeating β-glycosides. Microbes do express β-glycosidase activity, however, and 
thus the hypothesis predicts that when the β-glycosides of thymol reach microbial 
activity in the lower gut there should be sufficient microbial β-glycosidase activity to 
liberate thymol from the glycoside there by allowing it to be active. Accordingly, the 
objective of this research project was to compare the bactericidal activity of free thymol 
and the conjugated form, thymol-β-D-glucopyranoside, on Campylobacter jejuni and 
Campylobacter coli during pure culture and during co-culture with a β-glycosidase 
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expressing gut bacterium, Parabacteroides distasonis, as well as during mixed culture 
with populations of swine, bovine and avian gut bacteria. 
 
Materials and Methods 
Microbe sources 
 The present study used Campylobacter coli, Campylobacter jejuni, and 
Parabacteroides distasonis. Campylobacter coli was isolated from a dairy cow (103) 
and Campylobacter jejuni was isolated from a broiler processing facility (104). The 
Campylobacter strains were stored during long term maintenance in CryoCareTM 
Bacterial Preservers (Key Scientific Products, Round Rock, TX, USA) according to 
manufacturer’s instructions. Each strain was resuscitated for each experiment via initial 
24 h culture (39°C) in non antibiotic-supplemented Bolton broth (Oxoid Ltd, 
Basingstoke, Hampshire, UK) and subsequent plating on Campy Cefex agar prepared 
and used as described by (105). Isolated colonies were propagated after 48 h incubation 
at 42º C,  were picked and inoculated into Bolton broth supplemented with 0.33 µg of 
cefoperazone and 200 µg of cyclohexamide per mL, which after 24 h incubation (39°C) 
served as the stock culture for experiments described below. The Parabacteroides 
distasonis isolate, formerly classified as Bacteroides distasonis (106), was obtained from 
porcine cecal contents grown in continuous flow culture (107).  
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Tests of thymol and thymol-β-D-glucopyranoside against Campylobacter in pure or 
co-culture with β-glycosidase expressing gut bacterium, Parabacteroides distasonis  
The effects of thymol and β-D-thymol were tested on C.coli and C.jejuni, during 
both pure culture and co-culture with P. distasonis, were tested in two separate 
experiments conducted on separate days. Cultures were conducted in antibiotic-free 
Bolton broth that had been prepared anaerobically by boiling and then cooling on ice 
while under continuous stream of 100% N2 gas. Once cooled, 5% (v/v) laked horse 
blood (Lampire Biological Laboratories Pipersville, PA, USA) was added and 10-mL 
volumes of media were aseptically distributed to pre-sterilized 18 x 150 mm crimp top 
tubes using a modification of Hungate anaerobic method as described by Bryant (1972). 
The tubes were supplemented (in triplicate) with small volumes (0.1 and 0.16 mL first 
and second experiments, respectively) of stock solutions of thymol or thymol-β-D-
glucopyranoside (prepared in 10% ethanol) to achieve a final concentration of 1 mM. In 
each experiment, triplicate sets of tubes were also supplemented with the same volumes 
of 10% ethanol for use as controls. The tubes were inoculated with (0.2% vol/vol) C. 
coli in the first experiment or C. jejuni in the second experiment and the respective co-
cultures were also inoculated with P. distasonis (0.2% vol/vol). Tubes were closed and 
incubated upright without agitation at 39°C. Fluids were collected at intervals and 
analyzed colorimetrically for determination of ammonia (108) and bacteriologically for 
viable cell count enumeration of Campylobacter as routinely done in this laboratory 
(109, 110). Briefly, samples were serially diluted (10-fold) in 0.1 M sodium phosphate 
buffer (pH 7.34) and spread-plated on Campy Cefex agar. Inoculated Campy Cefex agar 
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plates were incubated at 42ºC under a microaerophillic (CO2:H2:N2) gas composition. 
Colonies were counted after 48-h incubation at 42°C. Gas chromatography analysis for 
free thymol (102) and pH measurements were made on remaining volumes of culture 
fluids from the pure and co-cultures of C. jejuni using. 
 Tests of thymol and thymol-β-D-glucopyranoside against Campylobacter culture 
with mixed populations of porcine, bovine or avian gastrointestinal tract microbes 
 To test the effect of thymol and thymol-β-D-glucopyranoside within mixed 
populations of gut bacteria, C. coli or C jejuni were cultured at 39°C under N2 in 
anaerobic Bolton broth inoculated with bovine or porcine feces, obtained fresh from a 
mature cow or sow, and with freshly collected crop or cecal contents obtained by 
necropsy from a market-aged broiler. Fecal, crop and cecal contents were inoculated into 
Boltons broth at 0.2 g per 100 mL and Campylobacter were inoculated at 0.2% vol/vol. 
In mixed culture experiments, test compounds were added in small volumes (0.1 mL) of 
concentrated stock solutions of thymol or thymol-β-D-glucopyranoside (each dissolved 
in a 62.5% ethanol solution) to achieve a 1 mM final concentration. Equal volumes of 
water or 62.5% ethanol were similarly added to control incubations. Fluid samples were 
collected from each of the mixed cultures at intervals during incubation for colorimetric 
determination of ammonia and bacteriological enumeration of Campy-Cefex agar for 
enumeration of Campylobacter as described earlier. Portions of fluid samples from the 
mixed porcine and bovine fecal incubations were also analyzed for pH and 
concentrations of volatile fatty acid by gas chromatography using the method of (111) 
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and representative samples from mixed cultures of bovine microbes were also subjected 
to GC analysis for determination of free thymol as described earlier. 
 Tests of orally administered thymol and thymol-β-D-glucopyranoside against crop 
and cecal Campylobacter and generic Escherichia coli following a short-term 
preharvest intervention 
 Twenty commercially-reared market-aged broilers were acquired from Sanderson 
Farms (College Station, TX) early morning (approximately 09:00) and transported 
within 50 minutes to the Southern Plains Agricultural Research Center facilities. Over 
the course of the next 30 minutes, eighteen of the broilers were allocated to their 
respective treatments (6 per treatment) via placement to randomly selected individual 
layer cages fitted with fresh floor paper to obtain fresh fecal droppings for cultural 
determination of pre-treatment Campylobacter and E. coli status. Birds treatment groups 
were orally gavaged that evening at 20:00 and again at 24:00 with 3-mL volumes of 20% 
ethanol solution or 25mM thymol or thymol-β-D-glucopyranoside (each prepared in 
20% ethanol), respectively. After the last treatment, the broilers were moved to a 
common floor pen (2.4 m x 3.6 m) bedded with fresh pine shavings. Ad libitum access to 
fresh water was provided in both rearing environments. The next morning at 09:00, each 
broiler was killed by cervical dislocation and necropsied within 1 h of harvest for 
collection of crop and cecal contents. Fecal droppings and contents were serially diluted 
(10-fold) in 0.1 M sodium phosphate buffer (pH 7.34) and spread-plated on to Campy 
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Cefex agar and to E. coli/Coliform Petrifilm (3M Microbiology, St, Paul, Mn) for 
enumeration of Campylobacter and E. coli (109, 110). 
Statistics 
 All incubations were performed in triplicate. Concentrations of ammonia, volatile 
fatty acids and log10 transformations of CFU mL-1 of C. coli and C. jejuni were tested for 
treatment effects at each sampling time by a general analysis of variance. For the in vitro 
studies, treatment means were compared to controls using a two-sided Dunnett’s 
Multiple comparison procedure.  For the in vivo animal study, multiple comparison of 
means were accomplished using a least significant differences were considered 
significant at P ≤ 0.05. All analysis Software were performed using Statistix© 9 
Analytical Software (Tallahassee, FL, USA). 
 Results 
Viable cell counts of C. coli during pure culture in medium supplemented with 1 
mM thymol were reduced from those of non-treated control cultures after 24 h of 
incubation (P< 0.05) but only tended (P= 0.0537) to be lower after 48 h (Figure 1A). 
When grown in pure culture with 1mM thymol-β-D-glucopyranoside, viable counts of C. 
coli were increased nearly 2.0 log10 CFU mL-1 (P< 0.05) from those of controls after 24 
h culture but were reduced, albeit not significantly, by 1.88 log10 CFU mL-1 from those 
of controls after 48-h culture. During co-culture with P. distasonis, viable counts of C. 
coli supplemented with 1 mM thymol were reduced from those of controls by 3.54 to 
4.30 log10 CFU mL-1 after 6, 24, and 48-h culture, respectively (Figure 1B). Viable C. 
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coli counts did not differ from control counts after 24 h culture in medium supplemented 
with 1 mM added thymol-β-D-glucopyranoside but were reduced from control counts by 
4.45 log10 CFU units mL-1 after 48-h culture with 1 mM thymol-β-D-glucopyranoside 
(Figure 1B).  
 
 
Figure 1. Viable cell counts during incubation of Campylobacter coli in pure culture (Figure A) or co-
culture with Parabacteroides distasonis (Figure B) incubated anaerobically (N2) at 39ºC in Bolton broth 
supplemented without (circles) or with either 1 mM thymol (squares) or thymol-β-D-glucopyranoside 
(triangles). Values are the mean ± SD from n = 3 cultures and asterisks indicate values differing from 
control values (P < 0.05).  
 
 
For pure cultures of C. jejuni, counts were reduced (P< 0.05) by 1.88 and 4.80 
log10 CFU mL-1 after 24 and 48-h incubation, incubation in Bolton broth supplemented 
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with 1mM thymol compared to controls but were not reduced in cultures treated with 
1mM thymol-β-D-glucopyranoside (Figure 2A). Conversely, when co-cultured with a β-
glycosidase expressing P. distasonis, counts of C. jejuni were reduced from those of 
controls by 6.43 and 6.87 log10 CFU mL-1 after 24 and 48-h, respectively, in cultures 
treated with 1 mM thymol (Figure 2B). As observed with C. coli, viable cell counts of C. 
jejuni were not reduced after 24 h, but were reduced after 48-h co-culture with P. 
distasonis in Bolton broth supplemented with 1 mM thymol-β-D-glucopyranoside, thus 
indicating that there was likely a lag in the hydrolysis of thymol from the glucose 
conjugate. 
 
 
Figure 2. Viable cell counts during incubation of Campylobacter jejuni in pure culture (Figure A) or co-
culture with Parabacteroides distasonis (Figure B) incubated anaerobically (N2) at 39ºC in Bolton broth 
supplemented without (circles) or with either 1 mM thymol (squares) or thymol-β-D-glucopyranoside 
(triangles). Values are the mean ± SD from n = 3 cultures and asterisks indicate values differing from 
control values (P < 0.05).  
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In thymol-treated cultures, thymol concentrations measured in fluid samples 
collected after 6, 24 and 48-h incubation of pure culture of C. jejuni averaged (± SD) 
0.52 ± 0.02, 0.48 ± 0.05 and 0.44 ± 0.01 µmol mL-1 and did not differ from each other (P 
> 0.05). However, these concentrations were decreased (P < 0.05) by approximately 48 
to 56% from the initial 1 mM added thymol. Similarly, thymol concentrations averaged 
0.58 ± 0.06, 0.64 ± 0.08 and 0.50 ± 0.04 µmol mL-1 in fluid samples collected after 6, 24 
and 48 h incubation of co-cultures of C. jejuni and P. distasonis and were decreased (P < 
0.05) by 36 to 50% from the initial 1 mM added thymol concentration. In co-cultures  
treated with 1 mM thymol-β-D-glucopyranoside, thymol accumulations were much 
lower even by 48-h of incubation (0.37 ± 0.02 µmol mL-1) and never exceeded 0.2 µmol 
mL-1 in pure cultures treated with 1 mM thymol-β-D-glucopyranoside. Ammonia 
accumulations measured after 24 and 48 h incubation of C. coli were lower (P < 0.05) 
than controls during pure culture, but accumulations varied considerably and 
consequently were not significantly different from untreated controls during co-culture 
with P. distasonis when supplemented 1 mM thymol or 1mM thymol-β-D-
glucopyranoside (Figure 3A and B). An effect of 1 mM thymol supplementation on 
ammonia accumulations was not observed after 6 h pure culture of C. coli, however, 
which probably reflects slow or lag phase growth during the early incubation period of 
this study. 
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Figure 3. Accumulation of ammonia during incubation of Campylobacter coli in pure culture (Figure A) 
or co-culture with Parabacteroides distasonis (Figure B) incubated anaerobically (N2) at 39ºC in Bolton 
broth supplemented without (circles) or with either 1 mM thymol (squares) or thymol-β-D-
glucopyranoside (triangles). Values are the mean ± SD from n = 3 cultures and asterisks indicate values 
differing from control values (P < 0.05). 
 
 
Ammonia accumulations measured after 24 and 48-h incubation of C. jejuni were 
lower (P < 0.05) than controls during pure as well as during co-culture with P. distasonis 
when supplemented with 1 mM thymol but not 1 mM thymol-β-D-glucopyranoside 
(Figure 4A and B). In the case of C. jejuni, pH measurements made at the end of the 48-
h incubation were unaffected by treatment during pure culture (P = 0.1679) and 
averaged 7.40 ± 0.19. An effect of treatment was observed (P = 0.0009) on pH during 
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co-culture, however, with the pH measured after 48-h co-culture with thymol (7.47 ± 
0.03) being higher (P < 0.05) than that measured in controls (7.22 ± 0.02). The pH in co-
cultures treated with thymol-β-D-glucopyranoside (7.23 ± 0.07) did not differ from 
controls. Measurements of pH were not made during pure or co-culture of C. coli. 
 
 
 
Figure 4. Accumulation of ammonia during incubation of Campylobacter jejuni in pure culture (Figure A) 
or co-culture with Parabacteroides distasonis (Figure B) incubated anaerobically (N2) at 39ºC in Bolton 
broth supplemented without (circles) or with either 1 mM thymol (squares) or thymol-β-D-
glucopyranoside (triangles). Values are the mean ± SD from n = 3 cultures and asterisks indicate values 
differing from control values (P < 0.05). 
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When grown in mixed culture, the freshly collected populations of porcine (Figure 5A) 
or bovine fecal microbes (Figure 5B), main effects of treatment were observed after 6 (P 
≤ 0.0016) and 24 h (P ≤ 0.0035) of culture. For mixed porcine and bovine population 
treated with 1 mM thymol, viable counts of C. coli and C. jejuni were reduced (P ≤ 0.05) 
from those of control by 3.11 and 4.74 log10 CFU mL-1, respectively, after 6 h incubation 
and were reduced (P < 0.05) to 3.25 and 2.50 log10 CFU mL-1, respectively, after 24 h 
incubation. For the mixed porcine populations treated with 1 mM thymol-β-D-
glucopyranoside, C. coli counts were reduced (P < 0.05) from those of controls by 2.02 
and 3.26 log10 CFU mL-1 after 6 and 24 h incubation, respectively. In the mixed bovine 
cultures treated with 1 mM thymol-β-D-glucopyranoside, C. jejuni counts did not differ 
(P > 0.05) from the control counts at the 6 h sampling time but were reduced (P < 0.05) 
from the controls by 2.40 log10 CFU mL-1after 24 h of incubation. 
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Figure 5. Viable cell counts of Camylobacter coli (Figure A) or Campylobacter jejuni (Figure B) during 
mixed culture of porcine or bovine gut microbes, respectively, incubated anaerobically (N2) at 39ºC in 
Bolton broth supplemented without (circles) or with either 1 mM thymol (squares) or thymol-β-D- 
glucopyranoside (triangles). Values are the mean ± SD from n = 3 cultures and asterisks indicate values 
differing from control values (P < 0.05). 
 
A main effect of thymol or thymol-β-D-glucopyranoside was not observed on 
ammonia accumulation by 6 h (P = 0.4372) mixed culture of porcine and bovine fecal 
microbe but an effect (P < 0.0001) was observed after 24 h culture, with accumulations 
in cultures treated with 1mM thymol or thymol-β-D-glucopyranoside being lower (P < 
0.05) than those of untreated controls (Figures 6A and B). 
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Figure 6. Accumulation of ammonia during mixed culture of Campylobacter coli or Campylobacter jejuni 
with porcine (Figure A) or bovine gut microbes (Figure B), respectively.  Cultures were incubated 
anaerobically (N2) at 39ºC in Bolton broth supplemented without (circles) or with either 1 mM thymol 
(squares) or or thymol-β-D-glucopyranoside (triangles). Values are the mean ± SD from n = 3 cultures and 
asterisks indicate values differing from control values (P < 0.05). 
 
 
A main effect of treatment (P ≤ 0.0142) was observed on accumulations of the 
fermentation acids acetate and propionate in the mixed cultures of porcine (7A and B) 
fecal microbes incubated 24 h, with accumulations by cultures treated with 1 mM 
thymol-β-D-glucopyranoside being reduced (P < 0.05) from those of the controls. 
Effects of treatment on accumulations of butyrate, valerate and branched chain fatty 
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acids isobutyrate and isovalerate were also observed (P ≤ 0.0192), with concentrations 
being decreased from those of controls in the mixed cultures of  porcine fecal microbes 
supplemented with 1 mM thymol-β-D-glucopyranoside (Figures 7A and B). 
 
 
 
Figure 7. Accumulation of fermentation acids during mixed culture of Campylobacter coli with porcine 
gut microbes. Cultures were incubated anaerobically (N2) at 39ºC in Bolton broth supplemented without 
(green) or with either 1 mM thymol (blue) or thymol-β-D-glucopyranoside (red). Values are the mean ± 
SD from n = 3 cultures and asterisks indicate values differing from control values (P < 0.05). 
  
 
Accumulations of the branched chain volatile fatty acids isobutyrate and valerate 
by mixed porcine cultures treated with 1 mM thymol were lower (P < 0.05) than those of 
controls but accumulations of the other volatile fatty acids did not differ. A main effect 
of treatment was observed (P ≤ 0.0226) on accumulations of acetate and propionate 
during mixed culture of C. jejuni with bovine fecal microbes (Figures 8A and B) with 
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accumulations in cultures treated with 1 mM thymol-β-D-glucopyranoside being lower 
than accumulations in non-treated controls. Treatment effects were not observed (P ≥ 
0.3564) on accumulations of any of the other volatile fatty acids in the mixed cultures of 
bovine fecal microbes. A main effect of treatment was observed on the final pH during 
(P = 0.0014 and 0.0046, respectively) mixed culture of the porcine and bovine fecal 
microbes. For the mixed porcine cultures, the final pH was higher (P < 0.05) in controls 
(6.90 ± 0.03) than in cultures treated with 1 mM thymol or 1 mM thymol-β-D-
glucopyranoside (6.75 ± 0.02 and 6.59 ± 0.09, respectively). In the case of the mixed 
bovine cultures, the final pH was higher (P <  0.05) in the thymol-treated (7.34 ± 0.31) 
cultures than in controls (6.62 ± 0.07), but the pH in cultures treated with thymol-β-D-
glucopyranoside (6.67 ± 0.11) did not differ from the controls.  
Free thymol accumulations in fluid samples collected from mixed cultures of 
bovine fecal microbes incubated with the addition of 1 mM free thymol were 0.93 ± 0.36 
and 0.77 ± 0.21 µmol mL-1 at 6 and 24 h and were not different (P > 0.05) than the 
amount added. Free thymol accumulations in fluid samples collected from mixed bovine 
fecal cultures treated with the addition of 1 mM thymol-β-D-glucopyranoside were 0.14 
± 0.02 and 1.28 ± 0.49 µmol mL-1 at 6 and 24 h, respectively 
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Figure 8. Accumulation of fermentation acids during mixed culture of Campylobacter jejuni with bovine 
gut microbes. Cultures were incubated anaerobically (N2) at 39ºC in Bolton broth supplemented without 
(green) or with either 1 mM thymol (blue) or thymol-β-D-glucopyranoside (red). Values are the mean ± 
SD from n = 3 cultures and asterisks indicate values differing from control values (P < 0.05). 
 
 
When cultured with mixed populations of freshly collected avian crop (Figure 
9A) or cecal microbes (Figure 9B), bacterial activity of both 1 mM thymol and 1 mM 
thymol-β-D-glucopyranoside against C. jejuni was again observed, but only after 24 h 
incubation. The magnitude of the bactericidal effect ranged from 1.10 to 2.32 log10 CFU 
mL-1 for these two compounds, which appears to be considerably less dramatic in the 
broiler crop and cecal populations than that observed with porcine or bovine fecal 
populations.  
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Figure 9. Viable cell counts of Campylobacter jejuni during mixed culture with avian gut microbes 
originating from the crop (Figure A) or ceca (Figure B). Cultures were incubated anaerobically (N2) at 
39ºC in Bolton broth supplemented without (circles) or with either 1 mM thymol (squares) or thymol-β-D-
glucopyranoside (triangles). Values are the mean ± SD from n = 3 cultures and asterisks indicate values 
differing from control values (P < 0.05). 
 
  
A main effect of treatment was not observed on the ammonia accumulations after 
6 or 24 h culture of C. jejuni (Figures 10A and B) and mixed populations of avian crop 
bacteria (P ≥ 0.5403). There was not a main effect of treatment observed after 6 h culture 
of mixed populations of avian cecal bacteria (P = 0.0341) on ammonia accumulations 
nor after 24 h mixed culture of avian cecal microbes, with ammonia concentrations 
being higher (P < 0.05) for cultures treated with 1 mM thymol or 1 mM thymol-β-D-
glucopyranoside than in untreated control cultures (Figure 10B). 
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Figure 10. Accumulation of ammonia during mixed culture of Campylobacter jejuni with avian gut 
microbes originating from the crop (Figure A) or ceca (Figure B). Cultures were incubated anaerobically 
(N2) at 39ºC in Bolton broth supplemented without (circles) or with either 1 mM thymol (squares) or 
thymol-β-D-glucopyranoside (triangles). Values are the mean ± SD from n = 3 cultures and asterisks 
indicate values differing from control values (P < 0.05). 
 
 
A main effect of treatment was observed on concentrations of viable 
Campylobacter (P = 0.0233) recovered from crop contents collected at necropsy. Counts 
were 1.2 log10 CFU mL-1 units lower in the contents from birds treated with thymol-β-D-
glucopyranoside than in birds treated with thymol (Figure 11). Recovery of viable 
Campylobacter in cecal contents was unaffected (P =0.1494) by treatment, recovery of 
viable E. coli spp. from crop or cecal contents was also unaffected (P = 0.8997 and 
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0.5601, respectively) (Figure 11). Ammonia accumulations in the crop and cecal 
contents were unaffected by treatment (P = 0.4994 and 0.2855, respectively) and 
averaged 0.06 ± 0.10 µmol NH3 g-1 crop content and 0.77 ± 0.34 µmol NH3 g-1 cecal 
content. 
 
 
 
Figure 11. Recovery of viable Campylobacter and Escherichia coli spp. from crop and cecal contents 
obtained upon necropsy of market aged broilers (n = 6 per treatment) twice-treated (approximately 11 and 
15 hr previously) via oral gavage with 3 ml volumes of 25 mM thymol (blue) or thymol-β-D-
glucopyranoside (red). Control birds (n = 6) were similarly treated with equal volumes of 20% ethanol 
(green). Values are the mean ± SD and where indicated with unlike lower case letters, values differ (P < 
0.05) based on an LSD comparison of means. 
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Discussion 
Results from the present study confirm the results from the earlier work of 
Anderson et al.(1) showing that 1 mM thymol markedly reduced the survivability of C. 
coli and C. jejuni both in pure and mixed culture with porcine and bovine gut microbes. 
Moreover, the 1 mM thymol treatment reduced the survivability of C. jejuni during 
mixed culture with avian crop and cecal microbes, although not to the same extent as in 
the bovine or porcine cultures. Numerous other studies have found that thymol is 
bactericidal to important foodborne pathogens with a minimum bactericidal 
concentrations reported to be 0.66, 1.10 and 1.55 mM for Escherichia coli K88, E. coli 
O157:H7 and Salmonella enterica serovar Typhimurium DT 104, respectively (112). 
Total anaerobes from the pig intestine were less susceptible to 1.72 mM thymol (26, 
113). Mechanistically, thymol is thought to exert its bactericidal effect via disruption of 
the bacterial cell wall (24), although the ability of thymol to inhibit deaminase activity 
has been proposed as a potential mechanism limiting the growth of assacharolytic 
Campylobacter (1). With respect to the latter mechanism, accumulations of ammonia 
were decreased in the present study by 1 mM thymol during pure culture of C. coli and 
C. jejuni as well as during co-culture with P. distasonis, albeit ammonia accumulations 
during co-culture of C. coli were not decreased significantly, likely because of the high 
amount of variability in ammonia measurements in these cultures. 
Despite the clearly evident bactericidal activity of thymol, its use as a preharvest 
feed additive to reduce the colonization of foodborne pathogens in the lower gut is likely 
limited because it is rapidly and extensively absorbed or degraded in the proximal 
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alimentary tract (101). Consequently, some researchers have proposed that encapsulation 
or other protection technologies will likely be needed to deliver effective concentrations 
of thymol to the lower gut to achieve in vivo reductions of Campylobacter. Whereas the 
use of natural and synthetic glycosidic conjugates to deliver pharmaceuticals to the colon 
has been used previously for a variety of other compounds (114), the use of β-glycosides 
to deliver thymol to the lower gut has not previously been investigated. Conceptually, if 
constructed properly intact β-glycosides should be resistant to absorption. In that regard, 
recent evidence has shown that the intact thymol-β-D-glucopyranoside glycoside is 
much more resistant to absorption, being absorbed across everted porcine jejunal 
segments at 1/3 the rate of free thymol (102). 
 Additionally, in monogastric animals the intact glycosides should be resistant to 
hydrolysis within the proximal alimentary tract, because higher animals are limited in 
their ability to produce β-glycoside-hydrolyzing enzymes. This activity is expressed in 
momogastrics by their populations of gut microbes colonizing the lower tract. Within 
pigs, for example, β-glycosidase activity is low or absent in the stomach and proximal 
small intestine. Activity does not become appreciable until the distal small intestine, 
cecum or large intestine where populations of competent hydrolyzing bacteria are 
established (115). Competent β-glycosidase expressing bacteria include certain species 
belonging to  Bacteroides, Bifobacteria, Clostridia, Enterobacteria, Enterococci and 
lactobacilli (116). The P. distasonis used in co-culture studies is also known to express 
β-glycosidase activity and is a normal inhabitant of gut habitats (117). 
 43 
 
In the present study, the 1 mM thymol-β-D-glucopyranoside treatment was  
inhibitory to C. coli and C. jejuni but this activity was significant only when co-cultured 
with  P. distasonis or when cultured with mixed populations of gut bacteria. These 
results provide evidence that the bactericidal activity of thymol-β-D-glucopyranoside 
was dependent on the presence of microbial populations possessing enzymatic activity 
capable of hydrolyzing the glycosidic bond. Conversely, the lack of an effect of thymol-
β-D-glucopyranoside on the recovery of viable C. coli and C. jejuni during pure culture 
is not unexpected considering there is no evidence that these two Campylobacter species 
express β-glycosidase (118). Furthermore, only very low amounts of free thymol (< 0.20 
mM) were measured in pure cultures of C. jejuni treated with thymol-β-D-
glucopyranoside and this may likely have been added as a contaminant of the 
synthesized thymol-β-D-glucopyranoside. 
 Similarly, ammonia accumulations were not significantly affected by thymol-β-
D-glucopyranoside during pure culture of C. coli and C. jejuni which suggests that 
appreciable amounts of free thymol were not made available to inhibit amino acid 
deamination. Significant effects of thymol-β-D-glucopyranoside were not observed on 
ammonia accumulation during co-culture either and this is contrary to what would be 
expected since the β-glycosidase activity of P. distasonis should liberate free thymol. It 
is possible, though, that the considerable contribution of P. distasonis to ammonia 
production may have masked an effect of any thymol potentially liberated during co-
culture. Moreover, the bactericidal effect of the 1 mM thymol-β-D-glucopyranoside 
against C. coli and C. jejuni during co-culture was not apparent until the 48-h sampling 
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period which suggests that the liberation of free thymol from the glucose conjugate 
occurred slowly and late during culture. The low recovery of free thymol (0.37 ± 0.02 
mM) from incubation fluids collected after 48 h co-culture of C. jejuni and P. distasonis 
provide further evidence the hydrolysis occurred slowly. Effects of thymol and thymol-
β-D-glucopyranoside treatment on ammonia production during mixed culture were 
dependent on the source of the mixed microbial population. For example, significant 
effects of 1mM thymol or 1 mM thymol-β-D-glucopyranoside treatment on ammonia 
accumulations were observed during culture of C. coli and C. jejuni with the respective 
porcine and bovine fecal populations. But again this inhibition did not occur until late 
during culture. 
When measured in fluid samples collected from the mixed bovine cultures, 
appreciable free thymol did not accumulate in the cultures treated with 1 mM thymol-β-
D-glucopyranoside until after 24 h. In contrast to that observed with the mixed 
populations of porcine and bovine microbes, ammonia accumulation by mixed 
populations of avian crop microbes were unaffected by treatment with 1 mM thymol or 
thymol-β-D-glucopyranoside and were increased in cultures of avian cecal microbes. 
The differential effects observed between the different populations are not readily 
explained but are likely to be population specific. 
From a practical perspective, it is reasonable to suspect that thymol-β-D-
glucopyranoside would be most suited for use as a feed additive in pigs because little 
hydrolysis of the glucose conjugate would be expected to occur within the pig stomach 
and proximal small intestine. Conversely, a major challenge to the use of thymol-β-D-
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glucopyranoside or other β-glycosidic-linked conjugates in ruminant or poultry is the 
presence of competent β-glycoside hydrolyzing microbial populations in their rumen or 
crop. For example, when live broilers in this study were orally treated with thymol or 
thymol-β-D-glucopyranoside, only thymol-β-D-glucopyranoside was effective in 
reducing Campylobacter and only in the crop. These results suggest that thymol was 
indeed absorbed very rapidly, perhaps as early as in the crop. Additionally, the lack of a 
thymol-β-D-glucopyranoside effect in the ceca suggests that the β-glycoside was 
extensively hydrolyzed in the crop and the liberated thymol was subsequently absorbed 
during passage to the ceca. The doses administered to the broilers were designed, based 
on estimates of gut volume, to deliver between 1 to 3 mM thymol or thymol-β-D-
glucopyranoside to the compartments and it is possible these doses may have been too 
low to allow sufficient passage of the compounds. For example, it is possible that higher 
doses may allow sufficient amounts to escape absorption or hydrolysis in the crop. 
Conversely, if additional encapsulation or the protective technologies could be used to 
deliver the intact glycoside to the lower gut, results from the in vitro study suggested that 
the compounds possibly could be active there. 
Importantly, however, results from the in vitro incubations with mixed 
populations of bovine fecal microbes revealed that thymol-β-D-glucopyranoside 
treatment markedly inhibited accumulations of major fermentative acids, acetate and 
propionate. The finding indicates that the thymol-β-D-glucopyranoside was a potent 
inhibitor of fermentation which likely will restrict its potential use as a preharvest feed 
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additive. Possibly, it could be administered as a terminal strategy, one given in the 
animals’ last meal or perhaps in the water upon arrival at the processing plant. 
In summary, results from the present studies extend the findings of thymols’ 
antimicrobial activity in addition to addressing the issues pertaining to absorption within 
the stomach and small intestine. These results demonstrated that thymol and thymol-β-
D-glucopyranoside inhibited C. coli and C. jejuni during pure culture, mixed populations 
of bovine, porcine and avian gut microbes. Bactericidal activity of thymol-β-D-
glucopyranoside against C. coli and C, jejuni was dependent on those mixed populations 
contributing β-glycosidase activity. Further studies are clearly needed to elucidate 
practical and economic issues pertaining to its use as a feed additive.  
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CONCLUSION 
  CHAPTER III
 Thymol-β-D-glucopyranoside was found to be much more resistant to absorption 
across the small intestine epithelium than free thymol.  This result indicates that the 
conjugate can resist absorption in the proximal alimentary and thus pass intact to the 
lower gut where it can be activated. In its conjugate form, thymol-β-D-glucopyranoside 
has little if any biological activity against Campylobacter or against ammonia 
accumulation. These results demonstrated that once activated (hydrolyzed) the conjugate 
thymol-β-D-glucopyranoside was effectively bactericidal against C. coli and C. jejuni 
and supported ammonia accumulation in mixed and pure cultures of bovine, porcine, and 
avian gut microbes.   
 The results from the pure and co-culture results also revealed the necessity of β-
glycosidase to activate (hydrolyze) the conjugate to promote the bactericidal activity of 
thymol. Thymol-β-D-glucopyranosides’ significant reduction of the fermentation amino 
acids suggests that the use of the conjugate as a feed additive would be anti-nutritional. 
This result indicates a need for strategic planning of when and how much to implement 
or use thymol-β-D-glucopyranoside as a feed additive.  In order to not affect the 
animals’ production, implementation or use in a terminal meal for delivery of thymol-β-
D-glucopyranoside seems most logical. The results from the in vivo avian study reveal 
the possible need for additional technologies or a dosage adjustment to prevent pre-
intestinal or pre-cecal hydrolysis of the conjugate and of course each animal will require 
a different strategy. 
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The development of a practical cost effective method to implement a pre-harvest 
control strategy could be instrumental in reducing the concentration and incidence of 
Campylobacter spp. and other microbial pathogens in food-producing animals. 
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